Related Experiment Video
Updated: May 12, 2026
A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy
Published on: November 7, 2017
Beyond gout: uric acid and cardiovascular diseases
1Division of Medicine and Surgery, Spedali Civili, Brescia, Italy.
Insights
Hyperuricemia and gout are linked to cardiovascular disease. Xantine-oxidase inhibitors show promise in preventing and treating cardiovascular issues, but more research is needed for clinical recommendations.
Area of Science:
- Cardiology
- Nephrology
- Rheumatology
Background:
- Hyperuricemia, characterized by elevated uric acid levels, is increasingly recognized as a significant risk factor for cardiovascular (CV) disease.
- Gout, a condition resulting from hyperuricemia, shares a complex relationship with CV complications.
Purpose of the Study:
- To review clinical and experimental evidence linking hyperuricemia and gout to cardiovascular outcomes.
- To evaluate the potential of xantine-oxidase (XO) inhibitors in managing CV risks associated with high uric acid levels.
Main Methods:
- A comprehensive literature search was conducted using PubMed to identify relevant clinical and experimental studies.
- Articles were selected based on their direct relevance to the association between hyperuricemia, gout, and cardiovascular disease.
Main Results:
- Evidence suggests a potential causal association between hyperuricemia and adverse CV outcomes.
- Studies indicate that XO inhibitors improve endothelial function, reduce oxidative stress, and enhance cardiac function.
- Improvements in hemodynamics and inflammatory markers were observed in patients treated with XO inhibitors.
Conclusions:
- Xantine-oxidase inhibitors represent a promising therapeutic strategy for mitigating CV consequences of hyperuricemia.
- While allopurinol and febuxostat show potential, further large-scale studies are necessary to establish definitive clinical recommendations for asymptomatic individuals with high CV risk.
Objectives:
This article discusses the results of clinical and experimental studies that examine the association of hyperuricemia and gout with cardiovascular (CV) disease.
Methods:
Key papers for inclusion were identified by a PubMed search, and articles were selected for their relevance to the topic, according to the authors' judgment.
Results And Conclusions:
Significant progress has been made in confirming an association, possibly causal, between hyperuricemia and CV outcomes. Xantine-oxidase (XO) inhibitors appear to be the most promising agents for prevention and treatment of CV consequences associated with hyperuricemia. Several small and medium sized studies have examined the effect of these agents on CV function in a variety of patient populations. Improvements in measures of endothelial function, oxidative stress, cardiac function, hemodynamics, and certain inflammatory indices have been demonstrated. Compounds for XO inhibition with more specific clinical effects and fewer side effects than allopurinol may be promising options to further explore the therapeutic potential in patients with CV disease. It is too early to make clinical recommendations with regard to the benefits of using XO inhibitor allopurinol or the novel febuxostat in patients with asymptomatic increased UA levels and high CV risk because only a small number of studies have shown that they may be beneficial in terms of CV outcomes. More studies are therefore needed to determine the potential of these drugs for reducing the risk of developing CV disease.
Related Concept Videos
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
01:30Coronary Artery Disease I: Introduction
01:26Urinary Tract Calculi II: Pathophysiology and Clinical Manifestations
01:30Peripheral Artery Disease I: Introduction
01:26Coronary Artery Disease IV: Preventive Measures
01:11Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...